33 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
that the COVID - 19 pandemic will continue to adversely impact our business, the risk that we may not be able to secure or retain coverage
424B5
NMTC
NeuroOne Medical Technologies Corp
26 Jul 23
Prospectus supplement for primary offering
4:24pm
of a potential global pandemic such as the COVID-19 pandemic on our business;
our ability to obtain reimbursement coverage for our cortical strip, grid
424B5
NMTC
NeuroOne Medical Technologies Corp
24 Jul 23
Prospectus supplement for primary offering
4:43pm
electrode technology;
our future development priorities;
the impact of a potential global pandemic such as the COVID-19 pandemic on our business;
our
8-K
EX-99.1
0tnqalhi o9
22 Dec 22
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
9:11am
424B5
ypu59fa 2q
22 Dec 22
Prospectus supplement for primary offering
6:43am
8-K
EX-99.1
bv4etslkkm979pcfwata
25 Oct 22
NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use
9:19am
8-K
EX-99.1
h9t5rft d5h07
14 Sep 22
Regulation FD Disclosure
8:30am
8-K
EX-99.1
zh0l8jt
11 Aug 22
NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
4:49pm
8-K
EX-99.1
unq33e
3 Aug 22
NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode
9:34am
8-K
EX-99.1
wvoqfl
2 Jun 22
NeuroOne® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders
4:05pm
8-K
EX-99.1
4gll1npt zaf8u0a5tal
16 May 22
NeuroOne Provides Evo® sEEG Update
4:38pm
8-K
EX-99.1
868s9yidnl
12 May 22
NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
4:17pm